Clincosm LogoSign in Get a demo

Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD

Sponsor
Emory University (Other)
Overall Status
Completed
CT.gov ID
NCT00605007
Collaborator
(none)
450
Enrollment
1
Location
46
Duration (Months)
9.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Hyperglycemia is a common complication of corticosteroid (cortisone) therapy. It is estimated that more than a third of patients with chronic pulmonary disease (COPD) exacerbation (16). Despite its frequency, the impact of corticosteroid-induced diabetes on clinical outcome and mortality is not known. A computerized search of biomedical journal literature from MEDLINE, PubMed, and Ovid from 1966 to 2006 provided very little information on the prevalence and outcome of corticosteroid-induced diabetes in patients with COPD. Therefore, the present study aims to evaluate the impact of corticosteroid-induced diabetes on clinical outcome in patients with COPD exacerbation. We will perform a retrospective chart review of all patients admitted to the hospital with COPD exacerbation from 1/01/05 to 06/30/06 at Grady Memorial Hospital. Medical records of all patients with COPD exacerbation treated with corticosteroids will be analyzed. Data on demographics, laboratory values, mortality rate, rate of hypoglycemic events, length of stay, as well as disposition at discharge will be analyzed.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Hypotheses:

    We hypothesize that COPD patients with corticosteroid-induced hyperglycemia experience higher morbidity (infections, ventilator associated pneumonia, length of stay, acute renal failure) and mortality compared to COPD patients with normal glucose levels.

    Specific Aim:

    To determine the impact of corticosteroid-induced hyperglycemia on clinical outcome (length of stay, disposition, APACHE score, need for ventilatory support and ICU admission, mortality) in patients with COPD exacerbation.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    450 participants
    Time Perspective:
    Retrospective
    Official Title:
    The Impact of Corticosteroid-induced Hyperglycemia on Clinical Outcome (Length of Stay, Disposition, APACHE Score, Need for Ventilatory Support and ICU Admission, Mortality) in Patients With COPD Exacerbation
    Study Start Date :
    Feb 1, 2006
    Actual Primary Completion Date :
    Jun 1, 2009
    Actual Study Completion Date :
    Dec 1, 2009

    Outcome Measures

    Primary Outcome Measures

    1. The primary outcome of the study is to determine the mortality rate of COPD patients with corticosteroid-induce hyperglycemia. [once all charts have been reviews]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: Patients admitted with COPD exacerbation

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Grady Memorial Hospital Atlanta Georgia United States 30303

    Sponsors and Collaborators

    • Emory University

    Investigators

    • Principal Investigator: Guillermo Umpierrez, MD, Emory University SOM

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Guillermo Umpierrez, Principal Investigator, Emory University
    ClinicalTrials.gov Identifier:
    NCT00605007
    Other Study ID Numbers:
    • IRB00001392
    • e1392
    First Posted:
    Jan 30, 2008
    Last Update Posted:
    Nov 21, 2013
    Last Verified:
    Apr 1, 2010
    Keywords provided by Guillermo Umpierrez, Principal Investigator, Emory University
    COPD
    Diabetes
    Respiratory Disorders
    Additional relevant MeSH terms:
    Hyperglycemia

    Study Results

    No Results Posted as of Nov 21, 2013